Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.
You may also be interested in...
Cardiolite MI Imaging Test Data May Prompt SPECT Practice Guideline
An emergency screening protocol for myocardial ischemia with single-photon emission computed tomography (SPECT) may be included in AHA/ACC practice guidelines as early as next year
Cardiolite MI Imaging Test Data May Prompt SPECT Practice Guideline
An emergency screening protocol for myocardial ischemia with single-photon emission computed tomography (SPECT) may be included in AHA/ACC practice guidelines as early as next year
DuPont Pictures Definity Imaging Agent Launch Supported By User Training
DuPont Pharmaceuticals plans to support an autumn launch of its Definity echocardiography ultrasound contrast agent with a user training program.